Statera Biopharma, Inc. · OTC:STAB
Statera Biopharma — Q3 2021 Earnings Presentation
11 slides from Statera Biopharma's earnings presentation, November 2021
Slide 1: Restoring Immune Health: 3Q 2021 Financial Results Conference Call
(NASDAQ: STAB) Restoring Immune Health 3Q 2021 Financial Results Conference Call 1 November 2021
Slide 2: Forward Looking Statements
FORWARD LOOKING STATEMENTS This presentation contains forward-looking statements that involve risks and uncertainties. All statements other than statements of current or historical fact contained in this presentation, including statements regarding the expected clinical development timeline for the
Slide 3: Rethinking Immunotherapies
RETHINKING IMMUNOTHERAPIES Statera Biopharma intends to become the leader in developing and commercializing therapies that help restore the immune system and keep it in homeostasis which we believe is safer and more effective Developing immunotherapies that restore dysfunctional immune systems to a
Slide 4: 2021-2022 Potential Catalysts
2021-2022 POTENTIAL CATALYSTS Potential Catalysts Potential Near-Term Catalysts (12-24 Months) • Phase 3 Crohn’s Study with STAT-201 • Expect to begin patient enrollment in 1Q22 • COVID Study with STAT-205 • Acute COVID-19 PK/ biomarker and safety study expected to begin patient Expected Studies enr
Slide 5: 3Q 2021 Financial Results
3Q 2021 Financial Results (NASDAQ: STAB) 5 November 2021
Slide 6: 3Q 2021 Financial Results
3Q 2021 FINANCIAL RESULTS • R&D expenses decreased from $4.4 million for 3Q20 to $3.4 million for the 3Q21 or 21.6% • The decrease is primarily attributable to one-time patent expenses totaling $3.8 million incurred in 2020 related to the transfer of intellectual property to old Cytocom by Immune Th
Slide 7: Financing Arrangements
FINANCING ARRANGEMENTS • Loan and Security Agreement, closed in April, 2021, with Avenue Venture Opportunities Fund • Drew down the full $15 million loan amount in May 2020 • Required to place $5 million of the proceeds in escrow, and the $10 million balance became available to use for general opera
Slide 8: Clinical Overview
Clinical Overview (NASDAQ: STAB) 8 November 2021
Slide 9: STAT-205: COVID Update
STAT-205: COVID UPDATE • Active IND for STAT-205 in COVID-19 • Expanding IND to Post-Acute COVID-19 • Initiating PK/biomarker and safety study in acute COVID-19 • Planning clinical study in the post-acute to evaluate safety and ability to improve disease progression or resolve long-term symptoms 9 N
Slide 10: Near-Term Pipeline Focus
NEAR-TERM PIPELINE FOCUS Initially targeting Autoimmune, Oncology and Hematology Autoimmune Oncology Hematology Acute Neutropenia & Crohn’s Disease Pancreatic Cancer Anemia (STAT-201) (STAT-401) (Entolimod™) 10 November 2021
Slide 11: Question and Answer Session
Question and Answer Session November 2021